Top news and stories from EWORLDWIRE http://www.eworldwire.com/ http://www.eworldwire.com/logos/logo40x60.gif http://www.eworldwire.com/ 40 60 (C) Copyright 2007 EWORLDWIRE Wed, 25 Jun 2008 09:40:15 -0400 http://www.eworldwire.com/pressreleases/18670 Response Scientific Inc. (RSI) today announced that its Receptor Biotech Division has developed a patented new prescription medication candidate that sensitizes the body's insulin receptors to perform more efficiently, thereby requiring less insulin to maintain healthy blood glucose levels. The discovery, code-named INS2, has demonstrated the ability to dramatically reduce the amount of insulin required by insulin-dependent people with Type 2 Diabetes by as much as 50 percent. [EWORLDWIRE] Tue, 24 Jun 2008 09:36:43 -0400